What's new? Log in Free sign up

IVERIC bio (ISEE) News and press releases

Company Profile

News

From Benzinga Pro

10 Health Care Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

Iveric Bio Announces Completion Of Rolling NDA Submission To FDA For Avacincaptad Pegol For The Treatment Of Geographic Atrophy

Biotech, News, FDA, General

IVERIC bio, Inc. (NASDAQ:ISEE) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the third and final part of its New Drug Application (NDA) for rolling review of avacincaptad pegol

10 Health Care Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

10 Health Care Stocks With Whale Alerts In Today's Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

Reported Late Wednesday, Iveric Bio Announces Pricing Of $300M Public Offering Of 13,350,000 Shares Of Common Stock At A Price Of $22.50/Share

News, Offerings

IVERIC bio, Inc. (NASDAQ:ISEE) (the "Company"), today announced the pricing of an upsized underwritten public offering of 13,350,000 shares of its common stock at a price to the public of $22.50 per share, less underwriting discounts and commissions.

Why InMed Pharmaceuticals Shares Tumbled 28%; Here Are 67 Biggest Movers From Friday

News, Penny Stocks, Short Sellers, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers AGBA Group Holding Limited (NASDAQ: AGBA) gained 50.7% to close at $6.78 on Friday.

Foot Locker, Ross Stores, Palo Alto Networks, And Other Big Gainers From Friday

News, Penny Stocks, Short Sellers, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

U.S. stocks closed higher on Friday, with the Dow Jones gaining around 200 points. Here is the list of some big stocks recording gains in the previous session.

Nasdaq Down 0.5%; Clearfield Shares Spike Higher

Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite dropping over 50 points on Friday.

Why PaxMedica Shares Are Trading Higher By Over 53%? Here Are 47 Stocks Moving In Friday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers PaxMedica, Inc. (NASDAQ: PXMD) gained 53.5% to $2.38 after the company announced an equity investment agreement for up to $20 million with Lincoln Park Capital.

12 Health Care Stocks Moving In Friday's Intraday Session

Nasdaq Turns Lower; Crude Oil Down Over 3%

Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite turning lower on Friday.

Dow Surges Over 100 Points; Foot Locker Earnings Top Views

Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday.

12 Health Care Stocks Moving In Friday's Pre-Market Session

Why Farfetch Shares Are Trading Lower; Here Are 26 Stocks Moving Premarket

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares rose 58.1% to $2.45 in pre-market trading. PaxMedica entered into committed equity investment agreement for up to $20 million with Lincoln Park Capital.

IVERIC bio Secures Breakthrough Therapy Tag For Its Flagship Geographic Atrophy Candidate

Biotech, News, Health Care, FDA, Movers, Trading Ideas, General

Gap, Palo Alto Networks And Some Other Big Stocks Moving Higher In Today's Pre-Market Session

News, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.

12 Health Care Stocks Moving In Thursday's After-Market Session

Iveric Bio Announces FDA Has Granted Breakthrough Therapy Designation For Avacincaptad Pegol For Geographic Atrophy

Biotech, News, FDA, General

- Designation based on 12-month primary endpoint data from GATHER pivotal trials - - Avacincaptad pegol (ACP) is the only investigational product for treatment of GA to achieve two positive phase 3 pivotal trials with

Analyst Ratings for IVERIC bio

Analyst Ratings

IVERIC bio (NASDAQ:ISEE) has observed the following analyst ratings within the last quarter:

Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Press releases

From Benzinga Pro

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IVERIC bio, Inc. (NASDAQ:ISEE) today reported that on January 3, 2023, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to twelve newly-hired, non-executive

Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directors

IVERIC bio, Inc. (NASDAQ:ISEE) announced today the election of Pravin U. Dugel, MD, President of Iveric Bio, to its Board of Directors, effective as of January 1, 2023. Dr. Dugel has been instrumental in helping to

Iveric Bio Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy

- Commercial launch preparations continue to accelerate - IVERIC bio, Inc. (NASDAQ:ISEE) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the third and final part of its New Drug

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IVERIC bio, Inc. (NASDAQ:ISEE) today reported that on December 1, 2022, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to nine newly-hired, non-executive

Iveric Bio Announces Pricing of $300 Million Public Offering of Common Stock

IVERIC bio, Inc. (NASDAQ:ISEE) (the "Company"), today announced the pricing of an upsized underwritten public offering of 13,350,000 shares of its common stock at a price to the public of $22.50 per share, less

Iveric Bio Announces Proposed Offering of Common Stock

IVERIC bio, Inc. (NASDAQ:ISEE) (the "Company"), today announced that it is commencing an underwritten public offering of $250.0 million of shares of its common stock. In addition, the Company intends to grant the

Thinking about buying stock in IVERIC bio, StoneCo, Twist Bioscience, Gap, or Foot Locker?

Opinion, Press Releases

NEW YORK, Nov. 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ISEE, STNE, TWST, GPS, and FL.

Iveric Bio Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy

- Designation based on 12-month primary endpoint data from GATHER pivotal trials - - Avacincaptad pegol (ACP) is the only investigational product for treatment of GA to achieve two positive phase 3 pivotal trials with

Iveric Bio to Present at Upcoming Investor Conferences

IVERIC bio, Inc. (NASDAQ:ISEE) announced today that Iveric Bio management will participate in fireside chats at the following investor conferences in November: Credit Suisse 31st Annual Healthcare Conference

Iveric Bio Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy

IVERIC bio, Inc. (NASDAQ:ISEE) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the first part of its New Drug Application (NDA) for rolling review of avacincaptad pegol (ACP, also

Iveric Bio Reports Third Quarter 2022 Operational Highlights and Financial Results

- Reported Positive GATHER2 Results for Avacincaptad Pegol in Geographic Atrophy - - Planned NDA Submission Moved Up to End of This Year - - Received Favorable Feedback from FDA on Intermediate AMD Development Plan